![Irene Schiller](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Irene Schiller active positions
Companies | Position | Start | End |
---|---|---|---|
Malcisbo AG
![]() Malcisbo AG Pharmaceuticals: MajorHealth Technology Malcisbo AG engages in the development of novel carbohydrate-based vaccines for human and animal health. It specializes in glycoengineering technologies to create novel and efficient glycoconjugate vaccines for unmet needs in human and veterinary medicine targeting large markets. Its vaccines target the medical areas of human Campylobacter infections and and porcine Actinobacillus pleuropneumoniae infections. The company was founded by Bruno Oesch, Irene Schiller, Markus Aebi and Lino Camponovo in May 2010 and is headquartered in Schlieren, Switzerland. | Chief Tech/Sci/R&D Officer | 2010-04-30 | - |
Founder | 2010-04-30 | - | |
University of Bern | Corporate Officer/Principal | - | - |
Career history of Irene Schiller
Former positions of Irene Schiller
Companies | Position | Start | End |
---|---|---|---|
Prionics AG
![]() Prionics AG Medical SpecialtiesHealth Technology Prionics AG engages in the research in as well as the development, production, and distribution of diagnostic solutions for farm animal diseases. It focuses on diseases that can be transmitted from animals to human beings such as mad cow's disease and other prion diseases. The company was founded by Bruno Oesch and Markus Moser on February 27, 1997 and is headquartered in Schlieren, Switzerland. | Sales & Marketing | - | - |
Training of Irene Schiller
University of Zurich | Doctorate Degree |
Statistics
International
Switzerland | 5 |
Operational
Chief Tech/Sci/R&D Officer | 1 |
Founder | 1 |
Sales & Marketing | 1 |
Sectoral
Health Technology | 3 |
Consumer Services | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Private companies | 2 |
---|---|
Malcisbo AG
![]() Malcisbo AG Pharmaceuticals: MajorHealth Technology Malcisbo AG engages in the development of novel carbohydrate-based vaccines for human and animal health. It specializes in glycoengineering technologies to create novel and efficient glycoconjugate vaccines for unmet needs in human and veterinary medicine targeting large markets. Its vaccines target the medical areas of human Campylobacter infections and and porcine Actinobacillus pleuropneumoniae infections. The company was founded by Bruno Oesch, Irene Schiller, Markus Aebi and Lino Camponovo in May 2010 and is headquartered in Schlieren, Switzerland. | Health Technology |
Prionics AG
![]() Prionics AG Medical SpecialtiesHealth Technology Prionics AG engages in the research in as well as the development, production, and distribution of diagnostic solutions for farm animal diseases. It focuses on diseases that can be transmitted from animals to human beings such as mad cow's disease and other prion diseases. The company was founded by Bruno Oesch and Markus Moser on February 27, 1997 and is headquartered in Schlieren, Switzerland. | Health Technology |
- Stock Market
- Insiders
- Irene Schiller
- Experience